Page 1 of 3
SOP DC0021.1
Version: 2
Bacterial Recombinant Protein
Development Initiation and Phase Change
Effective Date: June 11, 2015
BACTERIAL RECOMBINANT PROTEIN DEVELOPMENT CHECKLIST
Date: ____________________
Accession #___________
Internal Use Only
Company Name:
PO #:
Primary Contact:
Secondary Contact:
Phone:
Fax:
Phone:
E-mail:
E-mail:
Bill to:
Ship to:
Fax:
FedEx #: ______________________________
Overall Goals/Purpose:
Please describe the final goal or purpose of the protein being developed:
Attributes of the Protein:
Name:
Size (Amino Acids & MW):
Native source (is it a bacterial or
mammalian protein, etc.):
UniProt or NCBI
Reference #:
Any known membrane-spanning regions:
Any known disulfide bonds:
Protein Sequence:
Nucleotide Sequence:
Additional protein information:
MAINE BIOTECHNOLOGY SERVICES, INC.
1037R Forest Avenue Portland, Maine 04103 USA
800-925-9476 > 207-797-5454 > FAX: 207-797-5595
email: sales@mainebiotechnology.com www.mainebiotechnology.com
Page 2 of 3
SOP DC0021.1
Version: 2
Bacterial Recombinant Protein
Development Initiation and Phase Change
Effective Date: June 11, 2015
Attributes of the Expression Construct:
Will an expression construct be sent or does one need to be generated?
If expression construct needs to be generated, would you like us to coordinate synthesis & construct generation?
Fusion/Epitope tag:
Tag position:
Promoter:
Antibiotic resistance:
Vector name (attach map if possible):
Additional Questions:
Have you expressed this protein previously? If so can you provide information?
Any known references on the bacterial recombinant expression of this protein?
Does this protein possess any known toxicity issues?
If the protein localizes to the insoluble fraction, is a denatured/solubilized product acceptable?
If not, is the addition of a solubilizing tag (for example: MBP or GST) a possibility?
We strive for soluble expression. If the protein has an elevated risk of insolubility, we recommend the addition of a
solubilizing tag. Due to the inherent issues surrounding refolding, it is not part of our standard process/offering and
would only be pursued after additional conversations with the customer.
Additional Comments:
MAINE BIOTECHNOLOGY SERVICES, INC.
1037R Forest Avenue Portland, Maine 04103 USA
800-925-9476 > 207-797-5454 > FAX: 207-797-5595
email: sales@mainebiotechnology.com www.mainebiotechnology.com
Page 3 of 3
SOP DC0021.1
Version: 2
Bacterial Recombinant Protein
Development Initiation and Phase Change
Effective Date: June 11, 2015
INTRODUCTION TO MBS’S RECOMBINANT PROTEIN DEVELOPMENT STAFF
Contact
Position
E-mail
Ph. Ext.
Carrie Rice
Director of Sales
crice@mainebiotechnology.com
14
Abby Culberson
Sales Account Manager
aculberson@mainebiotechnology.com
10
Melissa Hamel
Recombinant Lab Research Scientist
mhamel@mainebiotechnology.com
21
Terms of Service:
Maine Biotechnology Services, Inc. (MBS) offers a full range of immunobiological services. Our goal is to
achieve the maximum level of satisfaction for all of our customers. We can guarantee that we will keep our
customers informed of their project status and we will involve our customer at all critical points during the
performance of their projects.
Many variables can impede the success of a recombinant protein project. Examples include lack of or poor
protein expression as well as protein insolubility. MBS is pleased to offer our knowledge and background
to assist in the successful conclusion of a project; however we cannot offer an absolute guarantee that we
can generate a soluble properly folded protein.
All projects and materials are completely confidential and the property of the client. We hope you
understand and appreciate our terms of service. If you have any questions or concerns, please do not
hesitate to contact us.
Thank you for choosing MBS.
MAINE BIOTECHNOLOGY SERVICES, INC.
1037R Forest Avenue Portland, Maine 04103 USA
800-925-9476 > 207-797-5454 > FAX: 207-797-5595
email: sales@mainebiotechnology.com www.mainebiotechnology.com